Weight‑loss injection drugs raise concerns over muscle loss and skin laxity

The rapid rise of injectable obesity treatments such as semaglutide and tirzepatide – popularly known as “Ozempic” and “Mounjaro” – has sparked widespread public interest in Brazil, France and beyond. Health experts warn that using these “weight‑loss pens” without a thorough metabolic assessment can lead to loss of muscle mass, a slowed metabolism and the so‑called “rebound” weight regain. Dr. Mateus Vilela cautions, “The risk is believing that the ‘pens’ alone solve the problem.”

Significant weight loss in a short period often outpaces the skin’s ability to retract, resulting in flaccidity, excess abdominal skin, reduced breast volume and other aesthetic concerns that patients describe as “Ozempic Body.” Plastic surgeon Pamela Massuia notes, “Patients are happy with the weight loss but then notice excess skin and flaccidity that affect self‑esteem.”

Guidelines from the World Health Organization and national obesity societies stress that obesity is a chronic, multifactorial disease requiring individualized treatment plans. Dr. Darwin Ribeiro emphasizes, “Improper weight loss can reduce weight on the scale but compromise muscle and metabolic health; the goal must be fat reduction while preserving muscle.” Sustainable strategies include lab testing, body‑composition analysis, balanced nutrition, strength training and ongoing medical follow‑up to avoid the “yo‑yo” effect.

The surge in effective pharmacologic options is also driving growth in body‑contouring surgeries worldwide, underscoring the need for comprehensive care that addresses both health and quality‑of‑life outcomes.